Lead Product(s): CT-388
Therapeutic Area: Endocrinology Product Name: CT-388
Highest Development Status: Phase I Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 24, 2021
CT-388 is a fully biased dual GLP-1 and GIP receptor modulator with a unique pharmacological profile optimized for improved tolerability at the GLP-1 receptor, anticipated to be dosed once-weekly.